Tofisopam is a 2,3-benzodiazepine anxiolytic used primarily to treat anxiety disorders, associated stress, and agitation in various European countries. Unlike classical 1,4-benzodiazepines, it lacks sedative, muscle relaxant, anticonvulsant, or amnestic effects, and does not bind to the standard benzodiazepine receptor. It works by inhibiting phosphodiesterase enzymes, particularly PDE-4A1, enhancing GABA activity to reduce excessive nerve cell firing, promote well-being, and alleviate psychological tension without impairing cognitive or psychomotor functions. This atypical profile makes it suitable for managing anxiety while supporting daily activities and energy levels.